Literature DB >> 28476228

Molecular Genetics of Thyroid Cancer in Children and Adolescents.

Andrew J Bauer1.   

Abstract

There has been a steady incorporation of powerful new molecular tools into the evaluation and management of thyroid nodules and thyroid cancer. With an increasing incidence of nodules and differentiated thyroid cancer (DTC) being diagnosed in children and adolescents, oncogene data are providing insight into the clinical differences between pediatric and adult patients with histologically similar DTC. However, additional investment and efforts are needed to define the genomic landscape for pediatric DTC with the goal of improving preoperative diagnostic accuracy as well as stratifying treatment in an effort to reduce complications of therapy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gene fusion; Indeterminate cytology; Molecular markers; Mutation; Oncogene; Thyroid cancer

Mesh:

Year:  2017        PMID: 28476228     DOI: 10.1016/j.ecl.2017.01.014

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  8 in total

1.  Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid Cancers.

Authors:  Aime T Franco; Julio C Ricarte-Filho; Amber Isaza; Zachary Jones; Neil Jain; Sogol Mostoufi-Moab; Lea Surrey; Theodore W Laetsch; Marilyn M Li; Jessica Clague DeHart; Erin Reichenberger; Deanne Taylor; Ken Kazahaya; N Scott Adzick; Andrew J Bauer
Journal:  J Clin Oncol       Date:  2022-01-11       Impact factor: 50.717

2.  Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions.

Authors:  Sogol Mostoufi-Moab; Emmanuel Labourier; Lisa Sullivan; Virginia LiVolsi; Yimei Li; Rui Xiao; Sylvie Beaudenon-Huibregtse; Ken Kazahaya; N Scott Adzick; Zubair Baloch; Andrew J Bauer
Journal:  Thyroid       Date:  2017-12-11       Impact factor: 6.568

3.  Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer.

Authors:  Aime T Franco; Julio C Ricarte-Filho; Theodore W Laetsch; Andrew J Bauer
Journal:  J Clin Invest       Date:  2021-09-15       Impact factor: 19.456

4.  Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients.

Authors:  Sébastien Perreault; Rose Chami; Rebecca J Deyell; Dina El Demellawy; Benjamin Ellezam; Nada Jabado; Daniel A Morgenstern; Aru Narendran; Poul H B Sorensen; Jonathan D Wasserman; Stephen Yip
Journal:  Curr Oncol       Date:  2021-01-09       Impact factor: 3.677

5.  NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.

Authors:  Young Ah Lee; Hyunjung Lee; Sun-Wha Im; Young Shin Song; Do-Youn Oh; Hyoung Jin Kang; Jae-Kyung Won; Kyeong Cheon Jung; Dohee Kwon; Eun-Jae Chung; J Hun Hah; Jin Chul Paeng; Ji-Hoon Kim; Jaeyong Choi; Ok-Hee Kim; Ji Min Oh; Byeong-Cheol Ahn; Lori J Wirth; Choong Ho Shin; Jong-Il Kim; Young Joo Park
Journal:  J Clin Invest       Date:  2021-09-15       Impact factor: 14.808

6.  Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape.

Authors:  Marloes Nies; Rena Vassilopoulou-Sellin; Roland L Bassett; Sireesha Yedururi; Mark E Zafereo; Maria E Cabanillas; Steven I Sherman; Thera P Links; Steven G Waguespack
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

7.  NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome.

Authors:  Xiaonan Zhao; Chelsea Kotch; Elizabeth Fox; Lea F Surrey; Gerald B Wertheim; Zubair W Baloch; Fumin Lin; Vinodh Pillai; Minjie Luo; Portia A Kreiger; Jennifer E Pogoriler; Rebecca L Linn; Pierre A Russo; Mariarita Santi; Adam C Resnick; Phillip B Storm; Stephen P Hunger; Andrew J Bauer; Marilyn M Li
Journal:  JCO Precis Oncol       Date:  2021-01-14

Review 8.  Thyroid Cancer in the Pediatric Population.

Authors:  Vera A Paulson; Erin R Rudzinski; Douglas S Hawkins
Journal:  Genes (Basel)       Date:  2019-09-18       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.